Retrospective validation of the postnatal Growth and Retinopathy of Prematurity (G-ROP) criteria in a Swiss cohort

Background Currently used screening criteria for retinopathy of prematurity (ROP) show high sensitivity for predicting treatment-requiring ROP but low specificity; over 90% of examined infants do not develop ROP that requires treatment (type 1 ROP). A novel weight gain-based prediction model was developed by the G-ROP study group to increase the specificity of the screening criteria and keep the number of ophthalmic examinations as low as possible. This retrospective cohort study aimed to externally validate the G-ROP screening criteria in a Swiss cohort. Methods Data from 645 preterm infants in ROP screening at Inselspital Bern between January 2015 and December 2019 were retrospectively retrieved from the screening log and analysed. The G-ROP screening criteria, consisting of 6 trigger parameters, were applied in infants with complete data. To determine the performance of the G-ROP prediction model for treatment-requiring ROP, sensitivity and specificity were calculated. Results Complete data were available for 322 infants who were included in the analysis. None of the excluded infants had developed type 1 ROP. By applying the 6 criteria in the G-ROP model, 214 infants were flagged to undergo screening: among these, 14 developed type 1 ROP, 9 developed type 2 ROP, and 43 developed milder stages of ROP. The sensitivity for predicting treatment-requiring ROP was 100% (CI, 0.79–1.00), and the specificity was 41% (CI, 0.35 –0.47). Implementing the novel G-ROP screening criteria would reduce the number of infants entering ROP screening by approximately one third. Conclusions The overall prevalence of treatment-requiring ROP was low (2.15%). Previously published performance parameters for the G-ROP algorithm were reproducible in this Swiss cohort. Importantly, all treatment-requiring infants were correctly identified. By using these novel criteria, the burden of screening examinations could be significantly reduced.

G-ROP Criteria for Predicting Retinopathy of Prematurity Among Neonates with Different Birth Weight Percentiles

Purpose: To determine whether being small for gestational age (SGA), appropriate for gestational age (AGA) and large for gestational age (LGA) affected the sensitivity and specificity of Postnatal Growth and Retinopathy of Prematurity (G-ROP) model. Methods: We applied the G-ROP criteria, except hydrocephalus, for prematures retrospectively. The infants were divided into three subgroups according to birth weight percentiles (SGA, AGA, LGA), and the performance of the G-ROP criteria was tested for each group by calculating sensitivity and specificity for any stage retinopathy of prematurity (ROP) and severe ROP. Severe ROP was defined as ROP needing treatment. Results: Three hundred and ninety neonates screened for ROP were included. The gestational age and birth weight of the neonates were 29.3±2.9 weeks and 1302.9±416 g, respectively. There were 41 (10.5%) SGA, 312 (80%) AGA and 37 (9.5%) LGA neonates. The sensitivity of the model for any ROP was 67.8%, 66.7%, 73.2%, 55.6% for all of the patients in the study, SGA, AGA, and LGA neonates, respectively. The sensitivity of the model for severe ROP in all group and for each subgroup was 100%. The specificity of the model for any ROP was 65.9%, 70.6%, 87.7%, 90% for all of the patients, SGA, AGA, and LGA neonates, respectively. The specificity for severe ROP was 46.4%, 50%, 44%, 63.6% for all of the patients, SGA, AGA, and LGA neonates, respectively.Conclusion: The sensitivity and specificity of the G-ROP model in SGA infants were similar with the whole group, but was different between SGA, AGA and LGA neonates. Although the model did not miss any severe ROP, the specificity of the model for severe ROP was found low.

Postnatal Growth Restriction in Preterm Infants: A Major Impact of Nutritional Practices and Methods of Assessment

Background: Nutritional management of preterm infants represents a significant challenge for most practitioners caring for sick and/or premature babies. Despite aggressive parenteral and enteral alimentation, a considerable number of preterm infants continue to fall far short of expected growth trajectories that match infants of similar gestation in-utero. Postnatal growth failure may be associated with future neurodevelopmental and cognitive impairments. Objective: The aim of the research is to investigate the incidence of postnatal growth restriction (PNGR) and characteristics of nutritional practices and growth parameters in a cohort of preterm infants born <32 weeks’ gestational age (GA) in a single neonatal intensive care unit (NICU). Methodology: This prospective study included 130 preterm infants born <32 weeks’ GA and admitted to the NICU between February 2018 and January 2020. The infants were divided into two groups: A (GA 23–26+6 weeks [n=50]) and B (27–31+6 weeks [n=80]). The association between PNGR and predicting risk factors was evaluated using logistic regression models. Results: PNGR was found in 62 (47%) infants at 28 days of life and increased to 73% of infants at 36 weeks’ postmenstrual age. Low birth weight and GA were independent factors predicting growth failure. PNGR was significantly correlated with birth weight (p < 0.01), length (p < 0.002), and GA (p < 0.03) at birth; however, HC was not a predictor of PNGR at 28 days. At 36 weeks’ PMA or discharge, PNGR was more pronounced in length, with a mean Z-score of -3.0, followed by weight, with a mean Z-score of -2.1, and an HC Z-score of -1.4. Conclusion : PNGR was significantly high in preterm infants <32 weeks’ gestation. A significant nutritional gap still exists between the recommended and actual caloric and protein supplementation, especially in the first few days after birth. Delayed optimization of caloric intake may be insufficient to promote growth trajectories, especially in preterm infants with significant morbidities.

GROWTH: Functional Data Analysis of the human height postnatal growth in an on-line application

Sledování individuálního růstu je v pediatrické praxi vyžadováno denně a často je doprovázeno potřebou podrobnějších analýz. Analýzu lidského růstu potřebují také sportovní antropologové a výzkumníci v oblasti biologie člověka. Přínosem by tedy byla pokročilá a zároveň snadno použitelná a bezplatná aplikace, která by pediatrům, auxologům a výzkumným pracovníkům v oblasti biologie člověka umožňovala provádět hloubkovou analýzu postnatálního růstu. Aplikace GROWTH byla vyvinuta na základě pochopení biologických procesů lidského růstu a matematických přístupů, které poskytují nejvhodnější model pro individuální (longitudinální) empirická data. Aplikace je navržena tak, aby ji bylo možné používat v každodenní pediatrické praxi. Poskytuje lékařům nástroje pro sledování růstu, předpovídání dosažené výšky a diagnostiku patologických růstových vzorců. Pokročilá analýza zahrnuje odhad časování hlavních růstových milníků. Současná verze je vyvrcholením několikastupňového vývoje aplikace a je založena na metodě FPCA (funkční analýza hlavních komponent) s numerickou optimalizací. Výstupní parametry jsou snadno použitelné a zobrazují se numericky i graficky.

Life Course Impact of Glucocorticoids During Pregnancy on Muscle Development and Function

Maternal stress, such as maternal obesity, can induce severe gestational disease and hormonal disorder which may disrupt fetal organ maturation and further cause endangered early or future health in offspring. During fetal development, glucocorticoids are essential for the maturation of organ systems. For instance, in clinical applications, glucocorticoids are commonly utilized to pregnant women with the risk of preterm delivery to reduce mortality of the newborns. However, exposure of excessive glucocorticoids at embryonic and fetal developmental stages can cause diseases such as cardiovascular disease and muscle atrophy in adulthood. Effects of excessive glucocorticoids on human health are well-recognized and extensively studied. Nonetheless, effects of these hormones on farm animal growth and development, particularly on prenatal muscle development, and postnatal growth, did not attract much attention until the last decade. Here, we provided a short review of the recent progress relating to the effect of glucocorticoids on prenatal skeletal muscle development and postnatal muscle growth as well as heart muscle development and cardiovascular disease during life course.

Intermittent maternofetal oxygenation during late gestation improved birthweight, neonatal growth, body symmetry, and muscle metabolism in intrauterine growth-restricted lambs

In humans and animals, intrauterine growth restriction (IUGR) results from fetal programming responses to poor intrauterine conditions. Chronic fetal hypoxemia elevates circulating catecholamines, which reduces skeletal muscle β2 adrenoceptor content and contributes to growth and metabolic pathologies in IUGR-born offspring. Our objective was to determine whether intermittent maternofetal oxygenation during late gestation would improve neonatal growth and glucose metabolism in IUGR-born lambs. Pregnant ewes were housed at 40°C from the 40 th to 95 th d of gestational age (dGA) to produce IUGR-born lambs (n = 9). A 2 nd group of IUGR-born lambs received prenatal O2 supplementation via maternal O2 insufflation (100% humidified O2, 10 L/min) for 8 h/d from dGA 130 to parturition (IUGR+O2, n = 10). Control lambs (n = 15) were from pair-fed thermoneutral ewes. All lambs were weaned at birth, hand-reared, and fitted with hindlimb catheters at d 25. Glucose-stimulated insulin secretion (GSIS) and hindlimb hyperinsulinemic-euglycemic clamp (HEC) studies were performed at d 28 and 29, respectively. At d 30, lambs were euthanized and ex vivo HEC studies were performed on isolated muscle. Without maternofetal oxygenation, IUGR lambs were 40% lighter (P &lt; 0.05) at birth and maintained slower (P &lt; 0.05) growth rates throughout the neonatal period compared to controls. At 30 d of age, IUGR lambs had lighter (P &lt; 0.05) hindlimbs and flexor digitorum superficialis (FDS) muscles. IUGR+O2 lambs exhibited improved (P &lt; 0.05) birthweight, neonatal growth, hindlimb mass, and FDS mass compared to IUGR lambs. Hindlimb insulin-stimulated glucose utilization and oxidation rates were reduced (P &lt; 0.05) in IUGR but not IUGR+O2 lambs. Ex vivo glucose oxidation rates were less (P &lt; 0.05) in muscle from IUGR but not IUGR+O2 lambs. Surprisingly, β2 adrenoceptor content and insulin responsiveness were reduced (P &lt; 0.05) in muscle from IUGR and IUGR+O2 lambs compared to controls. In addition, glucose-stimulated insulin secretion was reduced (P &lt; 0.05) in IUGR lambs and only modestly improved (P &lt; 0.05) in IUGR+O2. Insufflation of O2 also increased (P &lt; 0.05) acidosis and hypercapnia in dams, perhaps due to the use of 100% O2 rather than a gas mixture with a lesser O2 percentage. Nevertheless, these findings show that intermittent maternofetal oxygenation during late gestation improved postnatal growth and metabolic outcomes in IUGR lambs without improving muscle β2 adrenoceptor content.

Using Nature to Nurture: Breast Milk Analysis and Fortification to Improve Growth and Neurodevelopmental Outcomes in Preterm Infants

Premature infants are born prior to a critical window of rapid placental nutrient transfer and fetal growth—particularly brain development—that occurs during the third trimester of pregnancy. Subsequently, a large proportion of preterm neonates experience extrauterine growth failure and associated neurodevelopmental impairments. Human milk (maternal or donor breast milk) is the recommended source of enteral nutrition for preterm infants, but requires additional fortification of macronutrient, micronutrient, and energy content to meet the nutritional demands of the preterm infant in attempts at replicating in utero nutrient accretion and growth rates. Traditional standardized fortification practices that add a fixed amount of multicomponent fortifier based on assumed breast milk composition do not take into account the considerable variations in breast milk content or individual neonatal metabolism. Emerging methods of individualized fortification—including targeted and adjusted fortification—show promise in improving postnatal growth and neurodevelopmental outcomes in preterm infants.